{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:46Z","timestamp":1790951446814,"version":"4.1.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["S-000436 INFLUVAX"],"award-info":[{"award-number":["S-000436 INFLUVAX"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.vaccine.2025.127281","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:40:18Z","timestamp":1747734018000},"page":"127281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Guided design for the development of an evolution-proof influenza vaccine"],"prefix":"10.1016","volume":"59","author":[{"given":"Lauren","family":"Myburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn","family":"van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth J.M.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy R.","family":"van Beijnum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan W.","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127281_bb0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127281_bb0015","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/vaccines9091032","article-title":"An overview of influenza viruses and vaccines","volume":"9","author":"Nuwarda","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2025.127281_bb0025","doi-asserted-by":"crossref","first-page":"C8","DOI":"10.1016\/j.vaccine.2008.04.011","article-title":"Vaccination and antigenic drift in influenza","volume":"26","author":"Boni","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza virus: dealing with a drifting and shifting pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines9090979","article-title":"Review of influenza virus vaccines: the qualitative nature of immune responses to infection and vaccination is a critical consideration","volume":"9","author":"Chan","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127281_bb0045","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/biot.201400393","article-title":"Emerging influenza viruses and the Prospect of a universal influenza virus vaccine","volume":"10","author":"Krammer","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2025.127281_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13238-010-0008-z","article-title":"The emergence of pandemic influenza viruses","volume":"1","author":"Guan","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.vaccine.2025.127281_bb0055","first-page":"377","article-title":"Influenza a virus reassortment","volume":"385","author":"Steel","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0060","first-page":"461","article-title":"Influenza viruses from avian and porcine sources and their possible role in the origin of human pandemic strains","volume":"39","author":"Webster","year":"1977","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2025.127281_bb0065","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1038\/s41467-022-34611-z","article-title":"Influenza a virus reassortment in mammals gives rise to genetically distinct within-host subpopulations","volume":"13","author":"Ganti","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127281_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/00333549101250S305","article-title":"Influenza: the once and future pandemic","volume":"125","author":"Taubenberger","year":"2010","journal-title":"Public Health Rep"},{"key":"10.1016\/j.vaccine.2025.127281_bb0075","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature08182","article-title":"Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic","volume":"459","author":"Smith","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127281_bb0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2217\/fvl.13.18","article-title":"Influenza pandemics of 1918 and 2009: a comparative account","volume":"8","author":"Khanna","year":"2013","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0085","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.013309","article-title":"Adaptation of influenza viruses to human airway receptors","volume":"296","author":"Thompson","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2025.127281_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2183\/pjab.88.226","article-title":"Molecular basis of the structure and function of H1 hemagglutinin of influenza virus","volume":"88","author":"Sriwilaijaroen","year":"2012","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.vaccine.2025.127281_bb0095","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nrmicro3362","article-title":"Enabling the \u2018host jump\u2019: structural determinants of receptor-binding specificity in influenza a viruses","volume":"12","author":"Shi","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14760584.2020.1709827","article-title":"In-depth phylogenetic analysis of the hemagglutinin gene of influenza a(H3N2) viruses circulating during the 2016-2017 season revealed egg-adaptive mutations of vaccine strains","volume":"19","author":"Galli","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0105","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.127281_bb0110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00797-19","article-title":"Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs","volume":"93","author":"Dhakal","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0115","doi-asserted-by":"crossref","first-page":"E4353","DOI":"10.1093\/cid\/ciaa1927","article-title":"Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in immunocompromised adults","volume":"73","author":"Hughes","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127281_bb0120","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1080\/21645515.2021.1875761","article-title":"Factors influencing the immunogenicity of influenza vaccines","volume":"17","author":"Wen","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127281_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6020028","article-title":"Immune history and influenza vaccine effectiveness","volume":"6","author":"Lewnard","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038315","article-title":"Influenza vaccine effectiveness: new insights and challenges","volume":"11","author":"McLean","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0135","author":"CDC"},{"key":"10.1016\/j.vaccine.2025.127281_bb0140","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127281_bb0145","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1016\/j.vaccine.2019.08.024","article-title":"Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017\u20132018","volume":"37","author":"Bruxvoort","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0150","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/JVI.00137-12","article-title":"Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0155","doi-asserted-by":"crossref","first-page":"17757","DOI":"10.1073\/pnas.2004783117","article-title":"Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes","volume":"117","author":"Liao","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127281_bb0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4049\/immunohorizons.1900022","article-title":"Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice","volume":"3","author":"Choi","year":"2019","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.vaccine.2025.127281_bb0165","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0170","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127281_bb0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0180","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127281_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00018-10","article-title":"Influenza virus vaccine based on the conserved hemagglutinin stalk domain","volume":"1","author":"Steel","year":"2010","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.127281_bb0190","doi-asserted-by":"crossref","first-page":"eabe5449","DOI":"10.1126\/scitranslmed.abe5449","article-title":"Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates","volume":"13","author":"Darricarr\u00e8re","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0200","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.vaccine.2008.12.023","article-title":"A multi-valent vaccine approach that elicits broad immunity within an influenza subtype","volume":"27","author":"Huber","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.692151","article-title":"Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in combination-adjuvant elicits broad reactivity beyond the vaccine components","volume":"12","author":"Hernandez-Davies","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0210","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1126\/science.adi2396","article-title":"Coupling antigens from multiple subtypes of influenza can broaden antibody and T cell responses","volume":"386","author":"Mallajosyula","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127281_bb0215","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted Influenza Vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127281_bb0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10875-014-0054-z","article-title":"High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine","volume":"34","author":"Yam","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0225","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1016\/j.vaccine.2014.08.068","article-title":"Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children","volume":"32","author":"Nolan","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0230","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59\u00ae-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/508174","article-title":"Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza a\/H9N2 vaccine preparations","volume":"43","author":"Atmar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127281_bb0240","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic a\/H1N1 influenza vaccine in children 3 to < 9 years of age","volume":"31","author":"Nassim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127281_bb0245","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2014.11.018","article-title":"Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial","volume":"33","author":"Langley","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274943","article-title":"Dose-sparing effect of two adjuvant formulations with a pandemic influenza a\/H7N9 vaccine: a randomized, double-blind, placebo-controlled, phase 1 clinical trial","volume":"17","author":"Vanni","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127281_bb0255","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127281_bb0260","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza a (H1N1) vaccine in various age groups","volume":"361","author":"Zhu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0265","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0270","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/14712591003724662","article-title":"MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk","volume":"10","author":"Durando","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2025.127281_bb0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","article-title":"Design and evaluation of a safe and potent adjuvant for human vaccines","volume":"6","author":"Ott","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0280","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1002\/jps.23311","article-title":"AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method","volume":"101","author":"Klucker","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2025.127281_bb0285","series-title":"Humenza","author":"Assessment Report","year":"2010"},{"key":"10.1016\/j.vaccine.2025.127281_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030265","article-title":"From sharks to yeasts: squalene in the development of vaccine adjuvants","volume":"15","author":"Mendes","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.vaccine.2025.127281_bb0295","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with matrix M\u2122 adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0300","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1750-2659.2011.00256.x","article-title":"Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model","volume":"5","author":"Pedersen","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2025.127281_bb0305","article-title":"Advances in adjuvanted influenza vaccines","volume":"11","author":"Shichinohe","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127281_bb0310","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.micinf.2007.06.007","article-title":"Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge","volume":"9","author":"Ichinohe","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127281_bb0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-017-0043-3","article-title":"Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a phase 2 clinical trial","volume":"3","author":"Pillet","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0320","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/138945010790711932","article-title":"Advances in the structure-based Design of the Influenza a Neuraminidase Inhibitors","volume":"11","author":"Mitrasinovic","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.vaccine.2025.127281_bb0325","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2174\/092986710791299957","article-title":"Current advances in anti-influenza therapy","volume":"17","author":"Saladino","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.vaccine.2025.127281_bb0330","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-2659.2011.00304.x","article-title":"Influenza Neuraminidase","volume":"6","author":"Air","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2025.127281_bb0335","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1126\/science.1132745","article-title":"Epochal evolution shapes the phylodynamics of interpandemic influenza a (H3N2) in humans","volume":"314","author":"Koelle","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127281_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.it.2023.11.001","article-title":"Targeting neuraminidase: the next frontier for broadly protective influenza vaccines","volume":"45","author":"Wu","year":"2024","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0345","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1016\/j.vaccine.2020.08.067","article-title":"Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice","volume":"38","author":"McMahon","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/v15010200","article-title":"Broadly protective neuraminidase-based influenza vaccines and monoclonal antibodies: target epitopes and mechanisms of action","volume":"15","author":"Abbadi","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127281_bb0355","article-title":"The human antibody response to the influenza virus neuraminidase following infection or vaccination","volume":"9","author":"Rajendran","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127281_bb0360","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.127281_bb0365","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cmi.2016.07.007","article-title":"Functional balance between neuraminidase and haemagglutinin in influenza viruses","volume":"22","author":"Gaymard","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.127281_bb0370","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tim.2019.08.010","article-title":"Influenza a virus hemagglutinin-neuraminidase-receptor balance: preserving virus motility","volume":"28","author":"de Vries","year":"2020","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0375","doi-asserted-by":"crossref","first-page":"12531","DOI":"10.1128\/JVI.01889-13","article-title":"A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein","volume":"87","author":"Hooper","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0380","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1128\/JVI.00458-10","article-title":"Neuraminidase receptor binding variants of human influenza a(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?","volume":"84","author":"Lin","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033880","article-title":"Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity","volume":"7","author":"Richard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127281_bb0390","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1128\/JVI.74.14.6316-6323.2000","article-title":"Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics","volume":"74","author":"Wagner","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0395","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/JVI.02694-07","article-title":"Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza a virus","volume":"82","author":"Kreijtz","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0400","first-page":"3478","article-title":"Memory T cells established by seasonal human influenza a infection cross-react with avian influenza a (H5N1) in healthy individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.127281_bb0405","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/17460794.3.2.167","article-title":"The influenza matrix protein 2 as a vaccine target","volume":"3","author":"Saelens","year":"2008","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0410","doi-asserted-by":"crossref","first-page":"23545","DOI":"10.1021\/acsnano.3c06526","article-title":"Single-component multilayered self-assembling protein nanoparticles displaying extracellular domains of matrix protein 2 as a Pan-influenza a vaccine","volume":"17","author":"Braz Gomes","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2025.127281_bb0415","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12985-023-01994-4","article-title":"VLPs containing stalk domain and ectodomain of matrix protein 2 of influenza induce protection in mice","volume":"20","author":"Shi","year":"2023","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2025.127281_bb0420","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0902147","article-title":"Universal vaccine based on Ectodomain of matrix protein 2 of influenza a: fc receptors and alveolar macrophages mediate protection","volume":"186","author":"El Bakkouri","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0425","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41598-020-60783-z","article-title":"Immunization with DNA prime-subunit protein boost strategy based on influenza H9N2 virus conserved matrix protein M1 and its epitope screening","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127281_bb0430","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1099\/vir.0.029777-0","article-title":"Endogenously expressed matrix protein M1 and nucleoprotein of influenza a are efficiently presented by class I and class II major histocompatibility complexes","volume":"92","author":"Doucet","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0435","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-023-00620-2","article-title":"Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs","volume":"8","author":"Vatzia","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048322","article-title":"A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127281_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105877","article-title":"Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice","volume":"225","author":"Raha","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2025.127281_bb0450","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nsmb.1574","article-title":"Universal epitopes of influenza virus hemagglutinins?","volume":"16","author":"Wang","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0455","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1128\/JVI.06147-11","article-title":"Evidence for N-glycan shielding of antigenic sites during evolution of human influenza a virus hemagglutinin","volume":"86","author":"Kobayashi","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0460","doi-asserted-by":"crossref","first-page":"1126034","DOI":"10.3389\/fimmu.2023.1126034","article-title":"Glycan masking in vaccine design: targets, immunogens and applications","volume":"14","author":"Martina","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0465","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","article-title":"Current and Future Influenza Vaccines","volume":"25","author":"Yamayoshi","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0470","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0475","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature13087","article-title":"A predictive fitness model for influenza","volume":"507","author":"\u0141uksza","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127281_bb0480","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127281_bb0485","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01914","article-title":"Integrating influenza antigenic dynamics with molecular evolution","volume":"3","author":"Bedford","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2025.127281_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005526","article-title":"Identification of low- and high-impact hemagglutinin amino acid substitutions that drive antigenic drift of influenza a(H1N1) viruses","volume":"12","author":"Harvey","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.127281_bb0495","first-page":"47","article-title":"Influenza: prediction is worth a shot","volume":"507","author":"Koelle","year":"2014","journal-title":"Nat Publ Group"},{"key":"10.1016\/j.vaccine.2025.127281_bb0500","first-page":"E1701","volume":"113","author":"Neher","year":"2016","journal-title":"Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses"},{"key":"10.1016\/j.vaccine.2025.127281_bb0505","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04630-22","article-title":"Bioinformatics and structural analysis of antigenic variation in the hemagglutinin gene of the influenza a(H1N1)pdm09 virus circulating in shiraz (2013 to 2015)","volume":"11","author":"Mortazavi","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2025.127281_bb0510","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature14460","article-title":"Global circulation patterns of seasonal influenza viruses vary with antigenic drift","volume":"523","author":"Bedford","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127281_bb0515","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/vaccines9030257","article-title":"Strategies targeting hemagglutinin as a universal influenza vaccine","volume":"9","author":"Bullard","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0520","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.1900379","article-title":"A computationally optimized broadly reactive antigen subtype\u2013specific influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin","volume":"204","author":"Sautto","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0525","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41598-023-51024-0","article-title":"Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses","volume":"14","author":"Uno","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127281_bb0530","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00052-21","article-title":"Broadly reactive H2 hemagglutinin vaccines elicit cross-reactive antibodies in ferrets preimmune to seasonal influenza a viruses","volume":"6","author":"Reneer","year":"2021","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.127281_bb0535","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41467-021-21508-6","article-title":"Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus","volume":"12","author":"Bullard","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127281_bb0540","doi-asserted-by":"crossref","first-page":"33987","DOI":"10.1038\/srep33987","article-title":"Epigraph: a vaccine design tool applied to an HIV therapeutic vaccine and a Pan-filovirus vaccine","volume":"6","author":"Theiler","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127281_bb0545","doi-asserted-by":"crossref","first-page":"1143451","DOI":"10.3389\/fimmu.2023.1143451","article-title":"Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza a virus in swine","volume":"14","author":"Petro-Turnquist","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0550","doi-asserted-by":"crossref","first-page":"17","DOI":"10.32607\/20758251-2012-4-4-17-27","volume":"4","author":"Sedova","year":"2012","journal-title":"Recombinant influenza vaccines Acta Naturae"},{"key":"10.1016\/j.vaccine.2025.127281_bb0555","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","article-title":"FluBlok, a next generation influenza vaccine manufactured in insect cells","volume":"37","author":"Cox","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2025.127281_bb0560","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/vaccines12020143","article-title":"Immunogenic and protective properties of recombinant hemagglutinin of influenza a (H5N8) virus","volume":"12","author":"Rudometova","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0565","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2302099","article-title":"Recombinant or standard-dose influenza vaccine in adults under 65 years of age","volume":"389","author":"Hsiao","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0570","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2051013615595595","article-title":"Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults","volume":"3","author":"Cox","year":"2015","journal-title":"Therapeutic Adv Vaccines"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2025.127281_bb0575","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jip.2011.05.003","article-title":"A fast track influenza virus vaccine produced in insect cells","volume":"107","author":"Cox","year":"2011","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.05.056","article-title":"A quadrivalent recombinant influenza hemagglutinin vaccine induced strong protective immune responses in animal models","volume":"42","author":"Feng","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0585","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1098\/rstb.2001.0980","article-title":"Soluble recombinant influenza vaccines","volume":"356","author":"Fiers","year":"2001","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"10.1016\/j.vaccine.2025.127281_bb0590","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2174\/1381612824666180309125344","article-title":"Plant-produced recombinant influenza a vaccines based on the M2e peptide","volume":"24","author":"Mardanova","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.vaccine.2025.127281_bb0595","article-title":"Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicit protective immune responses against influenza viruses","volume":"2024.2002.2027.582355","author":"Zhang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2025.127281_bb0600","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00354-24","article-title":"Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses","volume":"98","author":"Uno","year":"2024","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0605","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/vaccines12121364","article-title":"Computationally optimized hemagglutinin proteins Adjuvanted with Infectimune\u00ae generate broadly protective antibody responses in mice and ferrets","volume":"12","author":"Allen","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0610","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41541-024-01014-8","article-title":"Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach","volume":"9","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/jgv.0.001765","article-title":"Message in a bottle: mRNA vaccination for influenza","volume":"103","author":"Shartouny","year":"2022","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0620","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0625","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/vaccines9111345","article-title":"The importance of RNA-based vaccines in the fight against Covid-19: an overview","volume":"9","author":"Machado","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127281_bb0630","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0635","doi-asserted-by":"crossref","first-page":"2336357","DOI":"10.1080\/21645515.2024.2336357","article-title":"Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines","volume":"20","author":"Russell","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127281_bb0640","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1038\/s41467-024-52940-z","article-title":"Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA","volume":"15","author":"Leonard","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127281_bb0645","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127281_bb0650","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127281_bb0655","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins\u202f: II. Immunological specificity of synthetic sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0660","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4615","article-title":"Glycoconjugate vaccines: principles and mechanisms","volume":"10","author":"Rappuoli","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127281_bb0665","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \"neglected valency\" - potential and limitations","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0670","doi-asserted-by":"crossref","first-page":"1294929","DOI":"10.3389\/fimmu.2023.1294929","article-title":"Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design","volume":"14","author":"Clemente","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127281_bb0675","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.vaccine.2018.03.064","article-title":"An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature","volume":"36","author":"Huijbers","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0680","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153958","article-title":"Vaccination against extracellular vimentin for treatment of urothelial Cancer of the bladder in client-owned dogs","volume":"15","author":"Engbersen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2025.127281_bb0685","doi-asserted-by":"crossref","first-page":"104719","DOI":"10.1016\/j.isci.2022.104719","article-title":"Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19","volume":"25","author":"Blanas","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2025.127281_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126989","article-title":"Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine","volume":"54","author":"Myburgh","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127281_bb0695","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500578X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500578X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T15:01:58Z","timestamp":1749567718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500578X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":138,"alternative-id":["S0264410X2500578X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127281","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guided design for the development of an evolution-proof influenza vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127281"}}